Recurrent Glioblastoma study: Bevacizumab
Official title Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
ClinicalTrials.gov ID: NCT05284643
What this study is testing
What is Bevacizumab?
An investigational intravenous drug being studied for recurrent glioblastoma. It is designed to inhibit blood vessel growth in tumors.
Also referred to as Avastin.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to see if a special MRI scan can help doctors target radiation more accurately to treat returning brain cancer.
- Who it's for
- This study is looking for people who have glioblastoma, a type of brain cancer, that has come back after previous treatment.
- What's involved
- Participants will receive a special MRI scan, proton radiation therapy, and a drug called bevacizumab (Avastin).
- Time commitment
- The source text does not specify the total duration or the number of visits required.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- An area of MRI enhancement consistent with glioblastoma outside of the initial high dose radiation field.
- Biopsy or resection proven recurrent glioblastoma.
- Progressive glioblastoma based on advanced imaging (brain positron emission tomography (PET), perfusion MRI, or clinical MR Spectroscopy) B.
- For "marginal" or "out of field" radiation failures where at least half of the enhancing disease is outside of the prior high dose radiation field...
- 28 days or 5 half-lives, whichever is shorter, elapsed from the administration of any experimental agent prior to initiation of study treatment.
You likely can't join if
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration.
- Transmural myocardial infarction within the last 6 months prior to registration.
- History of stroke or transient ischemic attack within 6 months prior to registration.
- Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease.
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of...
See the full eligibility criteria
- An area of MRI enhancement consistent with glioblastoma outside of the initial high dose radiation field.
- Biopsy or resection proven recurrent glioblastoma.
- Progressive glioblastoma based on advanced imaging (brain positron emission tomography (PET), perfusion MRI, or clinical MR Spectroscopy) B.
- For "marginal" or "out of field" radiation failures where at least half of the enhancing disease is outside of the prior high dose radiation field but there is field overlap, patients must have completed prior radiation...
- 28 days or 5 half-lives, whichever is shorter, elapsed from the administration of any experimental agent prior to initiation of study treatment.
- [urine protein]/[urine creatinine]: if both protein and creatinine are reported in mg/dL
- No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- In-range international normalized ratio (INR) (typically 2-3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin, within 21 days prior to registration
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration.
- Transmural myocardial infarction within the last 6 months prior to registration.
- History of stroke or transient ischemic attack within 6 months prior to registration.
- Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease.
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function other than screening panel (Section 3.1) and coagulation parameters are not...
- Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that HIV testing is not required for entry into this protocol.
The study team makes the final eligibility decision.
Where it is enrolling
- Miami, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Miami, Florida, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.